Related Experiment Video
Updated: Jan 19, 2026
06:23
Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
Published on: May 23, 2021
5.4K
Ceftriaxone use in brucellosis: A case series
Daniah F Fatani1, Walaa A Alsanoosi1, Mazen A Badawi2
1Pharmacy Practice Department, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Idcases
|September 20, 2019
Summary
Ceftriaxone shows promise in treating brucellosis, especially complicated cases. Six patients receiving ceftriaxone achieved clinical cure, indicating its potential as an effective antibiotic option for this zoonotic disease.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Brucellosis is a zoonotic disease caused by Brucella species, presenting as uncomplicated or complicated forms.
- Treatment typically requires multiple antibiotics, with limited data on specific agents like ceftriaxone.
- This study investigates the clinical utility of ceftriaxone in brucellosis treatment.
Observation:
- A retrospective review of 94 brucellosis patients identified six who received ceftriaxone (2g IV every 12h).
- These patients included four with neurobrucellosis, one with Brucella epididymo-orchitis, and one with uncomplicated brucellosis.
- Treatment durations varied, with one patient experiencing presumed antibiotic-induced fever leading to discontinuation.
Findings:
- All six patients treated with ceftriaxone achieved clinical cure.
- One neurobrucellosis case experienced complications despite treatment.
- Ceftriaxone was administered intravenously at a dose of 2g every 12 hours.
Implications:
- Ceftriaxone appears to be a viable option for managing complicated brucellosis when integrated into existing treatment regimens.
- Further research may elucidate optimal dosing and duration for ceftriaxone in brucellosis therapy.
- The findings support considering ceftriaxone as part of multi-drug therapy for Brucella infections.
